FDA Drug Approval, A213847, DAPSONE

FDA Drug Approval, A213847, DAPSONE

Regular price $149.00 USD
Regular price Sale price $149.00 USD
Sale Sold out
ANDA: 213847
Company: MYLAN
Drug Name: DAPSONE
Active Ingredients: DAPSONE
Strength: 7.5%
Dosage Form/Route: GEL;TOPICAL
Action Date: 02/04/2022
Marketing Status: Prescription
Submission Classification: ORIG-1 TE Code: AB

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

View full details